PDT Partners LLC Increases Stake in Cellebrite DI Ltd. (NASDAQ:CLBT)

PDT Partners LLC boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 385.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,842 shares of the company's stock after buying an additional 97,539 shares during the period. PDT Partners LLC owned approximately 0.06% of Cellebrite DI worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of CLBT. NewEdge Advisors LLC increased its holdings in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the period. R Squared Ltd purchased a new stake in shares of Cellebrite DI in the 4th quarter valued at about $100,000. Polen Capital Management LLC bought a new stake in shares of Cellebrite DI during the 4th quarter valued at about $222,000. Victory Capital Management Inc. purchased a new position in shares of Cellebrite DI during the fourth quarter worth about $234,000. Finally, HighTower Advisors LLC bought a new stake in Cellebrite DI during the fourth quarter valued at approximately $274,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Price Performance

Cellebrite DI stock traded down $0.24 during trading hours on Monday, reaching $19.90. The company had a trading volume of 377,696 shares, compared to its average volume of 1,416,946. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The company has a 50-day moving average price of $18.82 and a 200 day moving average price of $20.20. The firm has a market cap of $4.77 billion, a price-to-earnings ratio of -14.32, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CLBT shares. JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, Lake Street Capital upped their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.